Deep Insight

Deep Insight is built for the founders who walk into a meeting with a sensor, an algorithm, and a regulatory pathway, and walk out frustrated by every generalist VC who just asked them about ARR. The Tel Aviv fund focuses on deep-tech and hardware-heavy companies, and it accepts the longer timelines and harder validation work that those businesses require.

The thesis is built around the conviction that the next decade of healthcare progress depends on hardware, sensing, and the AI models that interpret what those sensors produce. That pushes the fund into AI/ML in healthcare and medical devices, with comfort across imaging, point-of-care diagnostics, novel sensors, surgical and procedural devices, and the algorithm layer sitting on top. The portfolio leans technical, often built around founders with serious engineering or clinical backgrounds, and the fund is willing to live with extended development cycles, regulatory approvals, and clinical evidence generation rather than chasing software companies with faster feedback loops.

Checks run from one to five million dollars, with the fund active across Seed, Series A, and Series B. That stage range is unusual for a fund of this size and lets Deep Insight maintain ownership through one or two follow-on rounds without dilution panic. Geography is anchored in Israel, with portfolio companies expected to address global markets, primarily the US and Europe. The fund is comfortable as a lead at Seed and as a meaningful participant in larger syndicates at Series A and B, especially when those rounds are structured around clinical milestones rather than revenue inflection.

The partnership operates with the patience that hardware and regulated products require. Founders should expect diligence that engages with the technical claims rather than skating across them, including conversations about clinical pathways, manufacturing scale-up, and IP defensibility. The team has the temperament to sit with complexity rather than retreat from it, which matters in deep-tech investing where surface-level pattern matching usually misleads.

Post-investment, Deep Insight focuses on the parts of company building that founders in deep-tech tend to underestimate. Regulatory strategy, especially around FDA and CE pathways, is treated as core rather than something to outsource. The fund engages on clinical study design, KOL development, and the transition from prototype to manufacturable product. It is candid that pure software companies, especially application-layer health IT plays, are not its specialty. Founders looking for a fund that treats hardware and algorithms as a single coherent product will find Deep Insight one of the more credible partners in the Israeli ecosystem. The fund will not paper over technical risk, but it will not refuse to take it either, and that combination is rarer than it should be at the Seed-to-Series-B end of the medical device and clinical AI market.